Sang Young Han
Overview
Explore the profile of Sang Young Han including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
39
Citations
306
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Moon S, Han S, Baek Y
J Liver Cancer
. 2023 Jun;
22(1):57-62.
PMID: 37383533
Currently, various tyrosine kinase inhibitors and immune checkpoint inhibitors have been suggested in the treatment guidelines for advanced hepatocellular carcinoma (HCC). However, sorafenib was the only systemic drug approved 10...
2.
Park J, Kim Y, Kim D, Bae S, Paik S, Lee Y, et al.
J Hepatol
. 2018 Dec;
70(4):684-691.
PMID: 30529387
Background & Aims: Sorafenib is first-line standard of care for patients with advanced hepatocellular carcinoma (HCC), yet it confers limited survival benefit. Therefore, we aimed to compare clinical outcomes of...
3.
Kim S, Baek Y, Han S, Lee S, Roh Y, Kim K, et al.
Korean J Gastroenterol
. 2018 Feb;
71(2):94-97.
PMID: 29471607
There are currently over 5,000-known species of mushrooms worldwide. Only 20-25% of mushrooms have been named, and 3% of these are poisonous. More than 95% of mushroom poisoning cases occur...
4.
Kim D, Lee S, Nam H, Jeon D, Park N, Nam Y, et al.
Korean J Gastroenterol
. 2016 Jun;
67(6):337-340.
PMID: 27312836
Sorafenib is currently the only targeted therapy available for advanced stage hepatocellular carcinoma (HCC). Cutaneous adverse events associated with sorafenib treatment include hand-foot skin reaction, but there has been no...
5.
Lee J, Kim Y, Roh Y, Roh K, Kim K, Kang S, et al.
Ann Surg Treat Res
. 2016 Mar;
90(3):147-56.
PMID: 26942158
Purpose: This retrospective study was an investigation of overall survival (OS), disease-free survival (DFS) and prognostic factors affecting OS and DFS in cirrhotic patients who received intraoperative radiofrequency ablation (IORFA)....
6.
Kim D, Kim H, Han K, Han S, Heo J, Woo H, et al.
Cancer Res Treat
. 2016 Feb;
48(4):1243-1252.
PMID: 26910470
Purpose: The purpose of this study is to report real life experiences of sorafenib therapy for hepatocellular carcinoma (HCC) in Korea, using a subset of data from GIDEON (Global Investigation...
7.
Kim J, Won R, Ban G, Ju M, Cho K, Han S, et al.
Sci Rep
. 2015 Jul;
5:12315.
PMID: 26189916
Hepatocellular carcinoma (HCC) has a high fatality rate and limited therapeutic options with side effects and low efficacy. Here, we proposed a new anti-HCC approach based on cancer-specific post-transcriptional targeting....
8.
Jo Y, Lee S, Han S, Baek Y, Ahn J, Choi W, et al.
World J Gastroenterol
. 2015 May;
21(16):5105-9.
PMID: 25945028
Nonconvulsive status epilepticus has become an important issue in modern neurology and epileptology. This is based on difficulty in definitively elucidating the condition and its various clinical phenomena and on...
9.
Jo Y, Lee S, Han S, Baek Y, Kim S, Kim W, et al.
World J Gastroenterol
. 2015 Feb;
21(6):1994-9.
PMID: 25684969
The development of boceprevir and telaprevir was a major step forward in the treatment of chronic hepatitis C. In addition, the treatment of these infections has been recently revolutionized by...
10.
Lee J, Lee S, Han S, Baek Y, Kim S, Rhyou H
World J Gastroenterol
. 2015 Feb;
21(6):1989-93.
PMID: 25684968
We present a rare case of intrahepatic cholangiocarcinoma (ICC) with multiple skeletal muscle metastases. The patient was a 55-year-old Asian woman presenting with abdominal pain; abdominal and pelvic computed tomography...